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AbstrACt 
Objectives The aim of this study was to describe the 
carrier prevalence and demographic variation of four 
different multiresistant bacteria (MRB) among acute 
patients in Danish emergency departments (EDs): 
methicillin-resistant Staphylococcus aureus (MRSA), 
carbapenemase-producing enterobacteria (CPE), extended-
spectrum beta-lactamase-producing enterobacteria 
(ESBL) and vancomycin-resistant enterococci (VRE), and 
to analyse the association of MRB carriage to a range of 
potential risk factors.
Design Multicentre descriptive and analytic cross-
sectional survey.
setting Eight EDs and four clinical microbiology 
departments in Denmark.
Participants Adults visiting the ED.
Main outcome measures Swabs from nose, throat and 
rectum were collected and analysed for MRSA, ESBL, VRE 
and CPE. The primary outcome was the prevalence of MRB 
carriage, and secondary outcomes relation to risk factors 
among ED patients.
results We included 5117 patients in the study. Median 
age was 68 years (54–77) and gender was equally 
distributed. In total, 266 (5.2%, 95% CI 4.6 to 5.8) were 
colonised with at least one MRB. No significant difference 
was observed between male and female patients, between 
age groups and between university and regional hospitals. 
Only 5 of the 266 patients with MRB were colonised with 
two of the included bacteria and none with more than 
two. CPE prevalence was 0.1% (95% CI 0.0 to 0.2), MRSA 
prevalence was 0.3% (95% CI 0.2 to 0.5), VRE prevalence 
was 0.4% (95% CI 0.3 to 0.6) and ESBL prevalence was 
4.5% (95% CI 3.9 to 5.1). Risk factors for MRB carriage 
were previous antibiotic treatment, previous hospital 
stay, having chronic respiratory infections, use of urinary 
catheter and travel to Asia, Oceania or Africa.
Conclusion Every 20th patient arriving to a Danish ED 
brings MRB to the hospital. ESBL is the most common 
MRB in the ED. The main risk factors for MRB carriage are 
recent antibiotic use and travel abroad.
trial registration number NCT03352167; Post-results.
bACkgrOunD
Multiresistant bacteria (MRB) is an increasing 
problem globally.1 2 In Denmark, attention has 
been focused on methicillin-resistant Staph-
ylococcus aureus (MRSA), but there has also 
been an increase in the prevalence of extend-
ed-spectrum beta-lactamase-producing 
enterobacteria (ESBL), vancomycin-resistant 
enterococci (VRE) and carbapenemase-pro-
cuding enterobacteria (CPE).3 4 
The consequences of the increasing bacte-
rial resistance to antibiotics are multiple 
and one of the greatest menaces to human 
health.5 6 Spread of MRB leads to increased 
healthcare costs, increased morbidity and 
mortality,7 increased risk of surgical site infec-
tion8 and complicates treatments of malig-
nancies and transplantations,9 10 which are 
dependent on effective infection control.
Antibiotics are used in many areas of the 
hospital. The emergency departments (EDs) 
are key players in the in-hospital use of 
strength and limitations of this study
 ► This is the first study to describe and analyse a 
large number of possible risk factors in acute 
adult patients screened for extended-spectrum 
beta-lactamase-producing enterobacteria, vanco-
mycin-resistant enterococci, methicillin-resistant 
Staphylococcus aureus and carbapenemase-pro-
ducing enterobacteria.
 ► It is a multicentre study covering the main part of 
Denmark.
 ► Many of the results are reported with some degree 
of uncertainty, reflected in wide CIs, especially in 
subgroup analysis.
 ► External validity of this study is restricted to coun-
tries with a low multiresistant bacteria prevalence.
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antibiotics and in the early identification of patients who 
are colonised with MRB since the vast majority of patients 
are admitted through these departments.
According to the Global Action Plan on antimicrobial 
resistance by WHO, one of the particularly important 
gaps in knowledge is information on incidence, preva-
lence, range across pathogens and geographical pattern 
related to antimicrobial resistance.6 There is currently 
very sparse knowledge about both prevalence and risk 
factors for colonisation with MRSA, ESBL, VRE and CPE 
in acutely admitted patients. In order to clarify the extent 
of the problem and to prioritise the preventive response 
to the spread of MRB, it is necessary to know the prev-
alence of these bacteria in patients passing through 
the EDs. To develop evidence-based screening tools to 
identify carriers of resistant bacteria among the acutely 
admitted patients, systematic collection of information 
on risk factors and exposures is required. Since a certain 
geographical variation in carrier prevalence is expected, 
it is desirable to include EDs from different geographical 
regions.
The aim of this study was first to describe the preva-
lence and demographic variation of MRSA, CPE, ESBL 
and VRE carriage among acute patients in eight different 
Danish EDs and second to analyse the association of MRB 
carriage to a range of potential risk factors.
MethODs
This study is part of the Danish multicentre study Anti-
biotic Resistance in Emergency Departments (AB-RED). 
The study protocol has been published and we refer to 
this publication for detailed information.11
The AB-RED study was designed as a multicentre 
descriptive and analytic cross-sectional survey of patients 
who were visiting one of eight Danish EDs geographically 
covering the whole country apart from the capital region.
The study was reported in accordance with the Strength-
ening the Reporting of Observational Studies in Epidemi-
ology guideline.12
study setting
The study took place in EDs at the university hospitals 
in Odense, Aarhus, Aalborg and Køge, and the regional 
hospitals in Aabenraa, Herning, Hjørring and Slagelse, 
which in total represent four of the five Danish regions. A 
Danish ED corresponds to an acute medical ward.
All the included EDs received patients, either referred 
by a general practitioner or the prehospital emergency 
medical services. The EDs and hospitals provide services 
at specialist level in emergency medicine, internal medi-
cine, cardiology, orthopaedic and surgery. All hospitals 
are public hospitals and provide care free of charge. 
There are no private acute care hospitals in Denmark.
Participant timeline
Enrolment to the study commenced on 8 January 2018. 
Due to local conditions, some of the participating 
departments included patients from 1 February 2018. 
Enrolment continued until the predefined sample size 
for each department had been reached. The last patient 
was enrolled in the end of April 2018.
sample size
A Danish study showed an MRSA prevalence in acutely 
admitted patients of 0.9% in an ED.13 It was assumed that 
VRE and CPE have a lower occurrence and ESBL a higher 
occurrence.3 We aimed at a national sample size of at least 
5000 patients, which would allow a prevalence of MRB of 
0.5% to be detected with 95% CI of ±0.14%, 1% preva-
lence with ±0.20% and 10% prevalence with ±0.6%.11
eligibility criteria
Patients >18 years of age, who presented to the EDs, were 
mentally competent and able to give consent were invited 
to participate in the study. Patients were excluded if they 
had been admitted >16 hours or if sampling from the 
rectum, nose or throat was hindered by anatomical or 
surgical reasons. Since the aim of the study was to assess 
the impact on the ED of MRB, patients who had been 
included before were allowed to be included again in a 
later admission.
In the study protocol, an inclusion criteria was that 
patients should have been at the department at least 
4 hours before enrolment. Due to differences in ED 
organising, it became difficult to maintain this criterion, 
thus this was deviated from the study protocol.
recruitment
Patients visiting the ED were contacted as early as possible 
during the enrolment process by a project employee who 
informed both verbally and in writing about the project. 
Privacy was secured during the information and no treat-
ment was delayed because of the enrolment. One hour of 
consideration time was offered to the patients.
Data collection methods
Interview
The project staff in the EDs had a healthcare background 
(nurse or medical student) and included patients from 
07:00 to 22:00 hours. All project staff received a ½ day 
training and supervised practice in interview and swab 
collection at the beginning of the project. Data quality 
and swab collection practice were supervised daily by the 
project manager and local coordinators.
All included patients were asked a range of questions 
concerning risk factors for carriage of MRB (online supple-
mentary appendix). The questions included were in part 
based on the Danish National Board of Health's guidance 
on preventing spreading of MRSA.14 In summary, these 
questions included demographical information, recent 
treatment with antibiotics, exposure to MRB in working 
places, especially different sorts of institutions, profes-
sional contact to animal farms, travelling activities and 
treatments in hospitals and clinics outside Denmark. In 
addition, questions about individual risk factors like skin 
and lung diseases were included.
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Collection of swabs
Immediately after the interview the patient was swabbed 
by the project staff. Swabs for MRSA were obtained from 
the mucosal surface of the anterior nares and the surfaces 
of the tonsils and pharynx (ESwab, Copan, SSI Diag-
nostica, Hillerød, Denmark). The sampling procedure 
followed the guidelines of the National Board of Health.
Rectal swabs for VRE, CPE and ESBL were obtained 
by rotating a swab against the mucosal surface 1–2 cm 
beyond the anal sphincter (FecalSwab, Copan).
The three swabs were labelled with barcodes containing 
information on project department and a unique project 
sequence number. All samples were sent to the regional 
department of clinical microbiology.
Outcomes
The primary outcome was the presence of MRB (MRSA, 
ESBL, VRE and CPE) in adult patients in the ED. The 
secondary outcome was the association between risk 
factors and MRB carrier stage.
Microbiological analysis
The collected samples were examined at the Departments 
of Clinical Microbiology at Aalborg University Hospital, 
Aarhus University Hospital, Odense University Hospital 
and Slagelse Hospital. The same method of analysis was 
applied to all four departments. All analyses followed the 
procedure described in the protocol article without devi-
ations from the protocol.11
Briefly outlined, samples were screened with commer-
cially available, selective, chromogenic agar media 
((MRSA: CHROMagar MRSA II agar, ESBL: CHROMagar 
ESBL bi-agar (Becton Dickinson, Heidelberg, Germany)), 
(CPE: chromID CARBA SMART agar, VRE: chromID VRE 
agar (bioMérieux, Marcy-l’Etoile, France)). A preceding 
enhancement broth step was used for both VRE and 
MRSA. All isolates were identified by mass spectrometry 
(Matrix-Assisted Laser Desorption-Ionization - time of 
flight) (MALDI-TOF)) and the presence of resistance 
genes in MRSA (mecA/mecC) VRE (vanA/vanB) and CPE 
(blaKPC/blaNDM/blaVIM/blaOXA-48/blaIMP) was confirmed by 
PCR. ESBL production was confirmed phenotypically 
(synergism between clavulanic acid and cefotaxime, 
ceftazidime and/or cefepime).
Data management and analysis
All patients were provided with a unique project sequence 
number, which was used throughout the project in the 
interviews and processing of microbiological samples 
to secure anonymity. The answers from the interviews 
were entered directly to an electronic questionnaire 
(SurveyXact, Rambøll, Aarhus, Denmark). Data were 
transmitted directly to central secured data file storage. 
Microbiological test results were merged with the inter-
view data using the project sequence number.
The carrier prevalence of the different MRB were 
calculated as percentage including a 95% CI, at regional 
level and national level and described with relation to 
region, hospital category, sex and age. We analysed differ-
ences between groups with Χ2 test or Fisher's exact test. 
Non-participant analysis was performed. The association 
between risk factors and MRB carrier stage was calcu-
lated using univariate logistic regression and multivariate 
logistic regression. Cochran’s rule was used and results 
expressed in ORs. The data analyses were conducted in 
STATA V.14 (Metrika, Stockholm, Sweden).
ethics approval and consent to participate
Informed written consent with signature was obtained 
from all participants before inclusion in the study. The 
patients had the right of revocation in which case the 
patient data would be deleted from the study.
Patient and public involvement
The patients were not involved in the development of the 
research question, the study design or in the recruitment 
to and conduct of the study.
All included patients were asked, if they wanted to be 
informed of the results of the microbiological analysis of 
their sample. If they did, answers on whether they were 
colonised with MRB and which type were sent individu-
ally by electronic mail. The mail included a statement on 
what the patient should do and who they could contact 
for further information.
results
In total, 7186 adult patients visiting the ED were invited 
to participate and 5117 (72%) of these were included in 
the analyses (figure 1 and table 1). The median age of 
Figure 1 Patient flow in the study. C, Central  Denmark; N, 
North Denmark; S, Southern Denmark; Z, Zealand.
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the study population was 68 years (IQR 54–77 years) and 
gender was equally distributed.
Among the patients who declined to participate, there 
were fewer male patients (46% vs 50%) and fewer patients 
with complains related to internal medicine (49% vs 
54%) than in the patients who accepted to participate. 
No age difference was found (67 years (IQR 46–80) vs 
68 years (IQR 54–77)).
Prevalence and demography of Mrb
In total, 266 (5.2%) of the patients were colonised with at 
least one MRB (table 2). There was no significant differ-
ence between male and female patients (5.5% vs 4.9%, 
p=0.33), between age groups (5.8% in those aged 50–64 
years vs 4.3% in those aged >80 years, p=0.11), between 
university hospitals and regional hospitals (5.3% vs 5.2%, 
p=0.81), but a significant difference between regions 
(Region of Central Denmark 6.5% vs Region of Northern 
Denmark 3.9%, p=0.004).
Of the 266 patients with MRB, five patients were 
colonised with two different MRB (ESBL/VRE in three 
patients, CPE/VRE in one patient and ESBL/CPE in one 
patient). No patients were colonised with more than two 
MRB.
Of the 5117 included patients, 96 (1.9%) were included 
more than once, and 10 (0.2%) more than twice. Of 
the 266 MRB-positive patients, 8 (3%) patients were 
re-attendances. Four (1.5%) of these re-attendances were 
colonised at all inclusions (three patients with ESBL and 
one with VRE).
CPE was detected in four patients (0.08%), three of 
these in Region Zealand. The MRSA prevalence was 0.3% 
nationally with significant differences between the regions 
(Region of North Denmark 0% vs Region of Central 
Denmark 0.8%, p=0.003). VRE was found in 0.4% of the 
patients, most common in the oldest group (18–40 years 
0% vs >80 years 0.9%, p=0.004), but with no significant 
differences between gender, region or type of hospital. 
The most common MRB colonisation was ESBL with a 
4.5% prevalence, ranging from 3.7% to 5.2% between the 
regions (p=0.09) and no significant differences between 
gender and age.
In table 3, number of in vitro susceptible isolates are 
reported.
risk factors for colonisation with Mrb
Table 4 reports a univariate analysis of the examined 
risk factors for MRB carriage for each bacterium. Since 
the number of colonised patients was low, we were only 
able to identify risk factors associated with MRB at multi-
variate level for ESBL. For CPE only four patients were 
identified, all were males and all had been admitted to 
hospital within the last 6 months. The risk of MRSA was 
increased among patients with chronic respiratory infec-
tions and patients previously colonised with MRSA. For 
VRE antibiotic treatment within past month, antibiotic 
treatment during the current admission, chronic obstruc-
tive pulmonary disease, treatment at a hospital in Nordic 
countries within last 6 months and treatment with anti-
biotics outside Nordic countries within the last 6 months 
were risk factors. The multivariate analysis reported that 
ESBL was associated with chronic respiratory infections, 
treatment with antibiotics outside Nordic countries and 
travel activity in Asia/Oceania.
DisCussiOn
We found that among 5117 patient visits to Danish EDs, 
266 (5.2%) had MRB, most commonly ESBL (4.5%), 
followed by VRE (0.4%), MRSA (0.3%) and CPE (0.08%). 
There were significant differences between the regions 
(from 3.9% to 6.5%), but not between type of hospital, 
age or gender.
Concerning risk factors for MRB, treatment with anti-
biotics within the last month (ESBL and VRE), chronic 
respiratory infections (MRSA and ESBL), treatment with 
antibiotics outside Nordic countries within the last 6 
months (CPE, ESBL and VRE), especially if the patient 
had been admitted to foreign hospital (CPE and ESBL) 
and travel activities to Asia/Oceania and Africa (ESBL) 
were associated with MRB.
The prevalence of antibiotic resistance is high in the 
southern and eastern parts of Europe and relatively low in 
the northern parts, especially in the Scandinavian coun-
tries and the Netherlands.2 The low carrier prevalence 
Table 1 Characteristics of analysed patients
Analysed
n=5117 
Median age, years (IQR) 68 (54–77)
  Male (49.7%) 68 (54–77)
  Female (50.3%) 68 (53–78)
Median time to lab, days (IQR) 1 (1–1)
Type of hospital, n (%)
  University hospitals 2203 (43%)
  Regional hospitals 2914 (57%)
Region, n (%)
  Zealand 1491 (29%)
  Central Denmark 1376 (27%)
  Southern Denmark 1195 (23%)
  North Denmark 1055 (21%)
Hospital, n (%)
  Regional Hospital West Jutland 811 (16%)
  Slagelse Hospital 777 (15%)
  Zealand University Hospital 714 (14%)
  North Denmark Regional Hospital 682 (13%)
  Hospital of Southern Jutland 644 (13%)
  Aarhus University Hospital 565 (11%)
  Odense University Hospital 551 (11%)
  Aalborg University Hospital 373 (7%)
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in Denmark probably reflects a long tradition for antimi-
crobial stewardship and restrictive use of antimicrobial 
drugs.
In the present study, median age is much higher than 
in the general population, since it is mostly older adults 
who visit the ED. Consumption of antimicrobial drugs is a 
risk factor for colonisation with MRB and thus the carrier 
prevalence in our study is presumed to be higher than the 
carrier prevalence in the community as the use of antibi-
otics is expected to be relatively high in elderly patients. 
The opposite might apply to MRSA as a large proportion 
of community-acquired MRSA in Denmark is associated 
with livestock contact and thus may be associated with a 
younger, working population.
The literature has mainly focused on the prevalence in 
patients admitted to the wards and less on acute patients. 
The carrier prevalence of ESBL has been reported 
1%–18%15–18 and risk factors for ESBL are admission to 
geriatric department, living in metropolitan area, recent 
antibiotic use, urinary catheter use, high level of care 
dependency, hospitalisation abroad and multiple hospital 
contacts,15–19 which is in line with our results. The preva-
lence of ESBL has been reported low in two UK studies20 21 
but 7%–30% in other studies.22–24 Reported risk factors 
are long hospital stays, recent antibiotic use and hospi-
talisation abroad.19 21 24 The prevalence of VRE has been 
reported from 0% to 25%16 20 25 26 and risk factors for VRE 
colonisation are increasing age, long hospital stay, inva-
sive devices and use of antibiotics.26 In a Danish ED in 
2015, an MRSA prevalence of 0.9% was reported.13 This 
prevalence is higher than the prevalence reported in 
the present study, which clearly conflicts with a general 
increase in the number of new cases of community-ac-
quired MRSA in Denmark.4 The reason is unknown but 
might reflect a temporary high local prevalence in 2015. 
In comparison, other studies have reported a preva-
lence of 2%–8%.15 16 27 Reported risk factors are chronic 
wounds, high level of care dependency, recent antibiotic 
use, readmission, previous MRSA colonisation, contact to 
living pigs, daily contact with children at nursery/kinder-
garten and renal failure.15 27 28
Despite the lack of studies investigating the prevalence 
in acute adult patients, the ED is thought to be a low prev-
alence department of MRB since the majority of patients 
come from the community.29 30 However, patients from 
nursing homes are frequently admitted and are reported 
to have a higher MRB carrier prevalence.31–33
Clinical considerations
On average, 1 out of 20 patients arriving to a Danish ED 
brings MRB to the hospital, which means that every day 
several patients will be handled with MRB. The current 
Danish screening programmes aim to identify MRSA 
and CPE, which are seen in fewer than 1:300 and 1:1250 
patients, respectively, suggesting that these patients are 
managed in the ED on a weekly or monthly basis only.
ESBL is currently the most frequent colonising MRB in 
the Danish EDs and careful monitoring of the incidence 
of ESBL infections is important to assess empirical anti-
biotic strategies. However, contact isolation is probably 
not required to prevent transmission of ESBL to other 
patients or staff in settings with a high standard in general 
and universal infection control.34
MRSA and CPE screening programmes based on 
patient information concerning risk situations are time 
consuming.28 The low MRB prevalence in this study 
suggests that the positive predictive value of these 
screening programmes could be very low leading to 
unnecessary interventions and contact isolations. This 
might affect the questions in the patient interview or 
Table 3 Number of in vitro susceptible isolates (%)*
Species
Number of 
isolates† Meropenem
Piperacillin-
tazobactam Gentamicin Ciprofloxacin Beta-lactamase
ESBL n=247 Escherichia coli 203 203 (100) 175 (86) 153 (75) 97 (48) na
Klebsiella 
pneumoniae
35 34 (97) 17 (49) 26 (74) 6 (17) na‡
Klebsiella 
oxytoca
6 6 (100) 4 (67) 2 (33) 1 (17) na
Other§ 2 2 (100) 1 1 1 na
CPE n=6 E. coli 3 0 0 1 (33) 0 OXA-48 (2),
NDM (2)¶
Other** 3 0 0 2 (67) 0 NDM (3)
*According to European Committee on Antimicrobial Susceptibility testing (EUCAST) breakpoints (www.eucast.org).
†Eleven patients were colonised with more than one ESBL-producing enterobacteria and two patients were colonised with two different CPE 
(different species or susceptibility pattern).
§One Klebsiella spp, and one Citrobacter koseri.
‡One isolate of K. pneumoniae was both ESBL and New Delhi metallo-beta-lactamase (NDM) positive.
¶One isolate was both oxacilinase-48 (OXA-48) and NDM positive.
**One Enterobacter cloacae, one K. pneumoniae and one Citrobacter freundii.
CPE, carbapenemase-producing enterobacteria; ESBL, extended-spectrum beta-lactamase-producing enterobacteria; na, not available.
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which bacteria to identify in the current screening 
programmes. This question will be addressed in another 
part of the AB-RED study.
The geographical variation in the prevalence of MRB 
might reflect variations in antibiotic use. In this study, 
we did not investigate the type of administered antibi-
otics or the duration of treatment prior to enrolment. 
These questions will be addressed in another part of the 
AB-RED study.
As travelling outside the Nordic countries is a risk 
factor for MRB colonisation, it seems rational that the 
national screening guidelines recommend screening 
of patients who have received antibiotics or in-hospital 
treatment outside the Nordic countries. Unfortunately, 
since patients transferred directly from foreign hospitals 
usually bypass the EDs and are admitted directly to the 
wards they are not included in this study.
strengths and weaknesses
The strength of the present study is that it is the first study 
to describe and analyse a large number of possible risk 
factors in acute adult patients screened for ESBL, VRE, 
MRSA and CPE. It is a large, semi-national multicentre 
study covering the main part of Denmark. Furthermore, 
the same methods for collecting information and biolog-
ical material and for microbiological testing were applied 
to all included departments/patients.
However, this study has also some limitations. First, 
while we aimed to include at least 5000 patient contacts, 
the optimal and expected inclusions were 10 000, as 
mentioned in the study protocol.11 This means that many 
of the results are reported with some degree of uncer-
tainty, reflected in wide CIs, especially in subgroup anal-
ysis of regional prevalences. Second, we only tested a 
sample of patients visiting the ED mainly on working days 
and only during day/evening time. We are therefore not 
able to describe the occurrences of MRB outside these 
periods. We do believe however, that time of admission is 
not influenced by MRB carrier stage. Third, the study did 
not include all patient contacts to ED during the collec-
tion periods, as only subset of patients could be managed 
by the study staff. This represents a possible selection bias 
but we do not have access to data which can be used to 
clarify this. Fourth, 28% declined to participate after being 
invited to the study, mainly because of no interest in the 
study. It was the study staffs' impression that other major 
reasons were the unpleasant rectal swab test and acute 
illness and fatigue. The results of the study might there-
fore represent a less ill ED population. A language barrier 
was the cause of exclusion in 32 patients. In Denmark, 
many workers in pig farms are often not Danish speaking. 
We do not know if there is a selection bias in this case. 
Furthermore, since more female patients and patients 
with internal medical complaints refused to participate, 
the results of the study might not represent the total 
population of patients in the ED. An inclusion crite-
rion was mentally competent. This criterion precludes 
patients with dementia, which usually stay in long-term 
care facilities where the MRB prevalence might be higher. 
Sixth, the questions are based on past events and require 
a certain level of recall ability for the acute ill patient.
Finally, the external validity of this study is restricted to 
countries with a low MRB prevalence.
COnClusiOn
Every 20th patient in a Danish ED brings MRB to the 
hospital, which means that every day several patients will 
be handled with MRB. ESBL is the most frequent MRB in 
the ED. Risk factors for MRB are recent use of antibiotics, 
chronic respiratory infections, recent treatment with anti-
biotics outside Nordic countries and travel activities to 
Asia/Oceania.
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